An introduction to clinical practice guidelines
In an ever more rapidly evolving and complex medical landscape, guidelines are paramount
for even the most experienced practitioner to ensure delivery of optimal and safe
care for patients. There is no doubt that modern clinical practice guidelines (CPG)
can make life a lot easier for practising physicians, and a lot safer for their patients,
as they often provide a stepwise algorithm which will walk physicians through the
important steps of decision-making during the diagnostic and therapeutic management
of their patients.
Medical guidelines have already been established thousands of years ago, as witness
papyrus finds dated back from the times of the Pharaohs of Egypt. Some may have been
empiric. Most were based on authority, beliefs, rituals or tradition.1
The modern era of CPGs begins in 1992, with the Institute of Medicine’s definition:
"Clinical Practice Guidelines are systematically developed statements to assist practitioner’s
decision about appropriate health care for specific clinical circumstances".2 They
are supposed to bridge the gap between research and current practice, and thus to
reduce inappropriate variability in practice.3
Modern clinical guidelines should be based on the highest quality of evidence according
to current data, leading to a general consensus in state-of-the-art diagnosis and
therapy of diseases, and a standardised approach to patient care. This is highly appreciated
in situations of multiple treatment options, in situation of sparse evidence, or of
uncertainty.4
Guidelines may be related to diseases or procedures. They are mainly developed for
diseases with high prevalence or frequently used medical procedures, high associated
costs and current variations in practice. They are of particular interest in diseases
in which diagnostic or treatment decisions may have a high impact on mortality, morbidity,
quality of life and care-related costs.5
The production of guidelines involves a technical and a social process: best evidence
has to be sought, gathered, and then be reviewed, interpreted and « translated » into
guidelines.5 The CPG may vary in their accuracy and quality according to the quality
and level of evidence they are based on, their methodology (form of verification,
update procedures, and so on) and the composition of the expert panel which will process
them. They may make evidence seem stronger when recommendations are based on low level
of evidence.
According to the producing institution, guideline recommendations may be purely based
on diagnostic and therapeutic efficiency, or incorporate features such as risk/benefit,
cost-effectiveness or safety considerations. They may vary according to the interests
of the establishing institution (eg, an insurer may have a different point of view
than a patient advocacy group or a physician’s association).
We have seen a massive rise in CPG in recent years, from local to international ones,
which are ever more easily disseminated due to the presence and spread of electronic
media. Far from all share the same level of evidence quality and reliability.
An oncologist will therefore have to look for well-validated, trustable guidelines
to work with. Fortunately, the practising oncologist can nowadays rely on several
sets of « trustable » unbiased guidelines widely available (European Society for Medical
Oncology (ESMO), National Comprehensive Cancer Network, and so on).
ESMO has excelled in delivering CPGs, which are established and regularly updated
by well-recognised expert panels, based on highest and clearly documented levels of
evidence. They are unbiased, patient-centred recommendations, independent of national
or other healthcare considerations and publicly, globally available, without restrictions.
Guidelines are made « ready for use » to be easily implemented into daily practice.
Due also to ESMO’s reputation as a foremost medical oncology society and its worldwide
broadly used portal esmo.org, ESMO guidelines are globally well disseminated among
the most recognised clinical guidelines in oncology, and have been endorsed and incorporated
by many national and other local authorities and societies.
Problems in guideline implementation
To be successful, a CPG has to be developed, disseminated to the right target audience
and finally be implemented. Without being adopted in daily practice, even the guideline
of highest quality is useless.
Some studies have raised substantial doubt about guideline implementation: It is estimated
that 30%–40% of all medical patients may receive treatments not based on guidelines.
Worse: 15%–20% may receive unnecessary or even harmful treatment.6–8
Barriers to guideline implementation have been well identified, and can be divided
into:
The implementing physician’s personal factors (knowledge and attitude).
Guideline-related factors.
External factors (lack of resources, organisational constraints, heavy workload, social
norms, and so on).4 9
We will not discuss external factors in this chapter, even though they have to be
identified as an explanation for CPG non-implementation, and will interest one part
of our knowledge and practice (K&P) questions.
Guideline-related barriers may be the easiest to resolve, but need to be identified:
poor layout, too high complexity or poor access to guidelines are rather easily tackled.
Guidelines have to be evidence based, plausible in their recommendation, applicable and
focused on well-defined patient groups.10
Personal factors (of the applying physician) need more complex interventions. Physicians
have to be motivated to use guidelines. This can be obtained providing earlier results
demonstrating benefits in survival or other goals when guidelines are successfully
implemented. A physician’s lack of knowledge or skills should be addressed by continuous
medical education (CME) efforts and audits. Some individuals may need to acquire a
learning culture. Finally, physicians may disagree with guideline contents. This may
be overcome through communication, that is, with opinion leaders, in educational meetings,
small group education, and even marketing outreach visits4 (the latter with an obvious
risk of potential bias). Pluridisciplinarity plays a major role, and tumour boards
may provide an excellent forum of consensus, translating CPG into individual physicians’
treatment decisions.
Validated efficient strategies to improve guideline implementation remain limited9
in often heterogeneous studies and disparate settings, which do not easily allow general
conclusions. A combination of multiple strategies is most certainly needed to overcome
barriers.7 11
ESMO Practising Oncologists Working Group guideline checklists: the why and how
Guidelines should be as short and user friendly as possible.11–13 They should be accessible
at the working place and easily integrated in daily routine. Considering the complexity
of diagnostic and therapeutic decisions in oncology on one side, and the necessity
to remain plausible and transparent on the other, delivering a combination of both
is a major challenge.
ESMO’s CPGs have become an ever more precise and user-friendly tool to guide practitioners
through procedures. Still, physicians may not take (or have) the time to go through
the detailed texts while consulting a patient or making a decision. Algorithms are
ever more complex to walk through as treatments become more and more personalised
and differentiated.
Clinicians may not apply medical procedures correctly both due to a lack of knowledge
of current standards or by accident. Some may be of major importance concerning later treatment
outcomes – or hamper further treatment decisions.
Checklists have been identified as one tool to raise CPG adherence.4 We consider that
they have a didactic role in recalling standard procedures, but also fulfil a documentation
role and could better structure the mandatory information needed to perform a multidisciplinary
tumour board (MTB) decision, in line with international CPGs. As MTB should be a mainstay
in oncologic decision-making for every patient, our checklists will also underline
their necessity to come to a therapeutic decision for any individual patient.
We therefore developed a set of checklists, which are entirely derived from current
ESMO guidelines.
Checklists: methods of development
The ESMO Practising Oncologists Working Group (POWG) has developed ESMO checklists.
Ten organ-specific checklists have been developed as of January 2018 (breast, early
and locally advanced non-small cell lung cancer (NSCLC), metastatic NSCLC, small cell
lung cancer, oesophageal cancer, gastric cancer, localised colon cancer, metastatic
colon cancer, non-metastatic rectal cancer, pancreatic cancer and prostate cancer).
The POWG also developed a general checklist to be considered in any treated oncologic
patient, regardless of the organ type. We are aware that all features will not be
available to every clinician, but hope that the guidelines will help encourage clinicians
to improve local standards to state-of-the-art needs.
The procedure to develop ESMO guideline checklists has been validated as follows: Designated
working group (WG) members identify all essential diagnostic steps to be included
to reach a clear MTB decision according to the corresponding guidelines in place.
Checklists are submitted to a designated WG editor for first review, and then submitted
to the ESMO Guidelines Committee chair for approval
Checklists: user guide
Checklists are printable or can be downloaded as templates. We imagined practitioners
might use them while consulting their patient, or when preparing an MTB meeting (or,
best, both).
When printed, users can use them to (check=ensure) make sure that all necessary items
have been asked for to be able to reach a treatment decision according to ESMO guidelines.
They can also serve as a document to be put in the patient file to document that all
exams had been ordered according to guideline recommendations.
When used as a template, ESMO checklists also provide space to enter diagnostic exam
results, thus presenting a sum-up and helping to summarise all steps up to (and including)
the MTB conclusion.
K&P questions
CME activities have also been identified as important tools to enhance guideline implementation.4
5
The POWG therefore designed specifically ESMO guideline-related short didactic questions
with ‘click-on’ immediate answers. K&P questions will be proposed on theesmo.org website.
Users are then asked a question related to their personal practice concerning the
topic.
The aim of this activity is twofold:
Short, playful quiz as regular, monthly CME activities, checking and enhancing knowledge
of current guidelines.
We still have a poor understanding concerning the implementation of ESMO guidelines
throughout Europe and the world. ESMO POWG will collect (anonymous) answers, which
may show differences in adherence to guidelines among participating physicians. This
may lead to hypothesis raising results (ie, a cluster of non-compliant answers in
one region may suggest unavailability of diagnostic procedures, scattered responses
may suggest lack of understanding, conflicting local guidelines, and so on) which
might be worth investigating.
K&P: methods of development
Designated POWG members produce clinical questions strictly based on ESMO guidelines
content. Questions are discussed internally among POWG members for pertinence. Once
written, they are cross-checked by all members and finally by a designated editor
on absolute fidelity with the corresponding guidelines.
For each question a number of five possible answers will be provided, of which only
one is accurate (and to be found in the corresponding ESMO guidelines). Of all answers,
one is completely wrong, while two are not adequate, and one answer could be considered
as ‘close’.
Questions will be graded according to the estimated level of difficulty.
A second question will only relate to the participant’s routine concerning the situation
dealt with in the first part (no ‘right’ or ‘wrong’ answers, no direct answer). The
answers will be anonymously collected and used for compliance evaluations of ESMO
guidelines.
Summary
In summary, trustworthy CPGs are paramount to practising oncologists in today’s fast
evolving medical landscape, for state-of-the-art management. Guidelines compliance
may vary even concerning the most pertinent guidelines, and may be substantially lower
than expected.
Therefore, knowledge concerning the level of guidelines adherence has to be gained.
Implementation tools and strategies have to be applied on multiple levels to enhance
compliance.
We provide two tools to enhance implementation of ESMO clinical guidelines, introducing
ESMO guidelines checklists and K&P questions.
Future analysis of download numbers and responses should provide us knowledge whether
these tools are useful to ESMO members in guideline implementation and whether current
practice reflects guideline recommendations.
These tools will be available on the website esmo.org as of the publishing date of
this article.